

Special Issue

Epidemiology of COVID-19

Message from the Guest Editors

The Coronavirus disease- 2019 (COVID-19) pandemic, caused by the novel virus, Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has had devastating consequences worldwide, with over one hundred million cases confirmed and nearly 2.3 million deaths reported as of February 3, 2021. The complex and heterogeneous expansion of the pandemic has highlighted the critical importance of global surveillance efforts and science-based public health decision-making and policies. Recently, the description of virus variants and emergent lineages has raised concerns regarding increased infectivity and virulence, potentially reshaping the epidemiologic landscape of this disease. This special issue will present emerging concepts regarding the epidemiology, prevention and control of SARS-CoV-2 infection, with special focus on ecological & evolutionary factors in virus emergence, host- virus dynamics, and the assessment and implementation of therapeutic and immunization efforts to mitigate disease burden.

Guest Editors

Prof. Dr. Alberto E. Paniz-Mondolfi

Icahn School of Medicine at Mount Sinai, Department of Pathology, Molecular and Cell-Based Medicine, Clinical Microbiology Laboratory, New York, NY 10029, USA

Dr. Emilia Mia Sordillo

Icahn School of Medicine at Mount Sinai, Molecular and Cell-Based Medicine Clinical Microbiology Laboratory, New York, NY 10029, USA

Deadline for manuscript submissions

closed (31 October 2021)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/76567

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.5 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).